Probi Valuation

Q: What is the Fair Price of PROB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

PROB (SEK346) is trading above our estimate of [[fair value]] (SEK277.07)

Is PROB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PROB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PROB (SEK346) is trading above our estimate of fair value (SEK277.07)

Significantly Below Fair Value: PROB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PROB?

Key metric: As PROB is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PROB. This is calculated by dividing PROB's market cap by their current revenue.
What is PROB's PS Ratio?
PS Ratio	6.3x
Sales	SEK 630.39m
Market Cap	SEK 3.94b

PROB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.8x
Enterprise Value/EBITDA	45.5x
PEG Ratio	5.8x

Price to Sales Ratio vs Peers

How does PROB's PS Ratio compare to its peers?

The above table shows the PS ratio for PROB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16.3x
DVYSR Devyser Diagnostics	11.3x	31.4%	SEK 2.2b
BIOG B BioGaia	7.9x	11.1%	SEK 10.7b
EGTX Egetis Therapeutics	29.6x	81.7%	SEK 2.0b
CRNO B Cereno Scientific	16.5x	-171.6%	SEK 1.4b
PROB Probi	6.3x	5.3%	SEK 3.9b

Price-To-Sales vs Peers: PROB is good value based on its Price-To-Sales Ratio (6.3x) compared to the peer average (16.3x).

Price to Sales Ratio vs Industry

How does PROB's PS Ratio compare vs other companies in the SE Biotechs Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap
XBRANE Xbrane Biopharma	1.4x	61.1%	US$24.69m
SPRINT Sprint Bioscience	2x	27.6%	US$11.06m
PMDS PMD Device Solutions	0.9x	62.0%	US$3.37m
GEAN Genetic Analysis	1.2x	n/a	US$2.14m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: PROB is good value based on its Price-To-Sales Ratio (6.3x) compared to the Swedish Biotechs industry average (11.9x).

Price to Sales Ratio vs Fair Ratio

What is PROB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PROB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.3x
Fair PS Ratio	1.9x

Price-To-Sales vs Fair Ratio: PROB is expensive based on its Price-To-Sales Ratio (6.3x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£162.7b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,454.00

4.0%

10.9%

Camurus

SEK 32.9b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.

CAMX

SEK 559.50

2.8%

23.7%

Corline Biomedical

SEK 137.5m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.40

-2.4%

-46.7%